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Table S1:  ICD-9-CM (International classification of diseases, ninth revision, clinical 
modification) codes and CPT-4 (Current Procedural Terminology, 4th Edition) codes used in 
the study. 
Category Code Type Code Description 
All glaucoma (for exclusion 




Primary open angle glaucoma 




365.11 primary open angle glaucoma  
ICD-9-CM 
Diagnosis 
365.12 low tension open-angle glaucoma  
















CPT-4 66160 fistulization of sclera for glaucoma sclerectomy with 
punch or scissors, with iridectomy 
CPT-4 66170 fistulization of sclera for glaucoma trabeculectomy ab 
externo in absence of previous surgery 
CPT-4 66172 fistulization of sclera for glaucoma trabeculectomy ab 
externo with scarring from previous ocular surgery or 
trauma (includes injection of antifibrotic agents) 
CPT-4 66174 transluminal dilation of aqueous outflow canal without 
retention of device or stent 
CPT-4 66175 transluminal dilation of aqueous outflow canal with 
retention of device or stent 
CPT-4 66180 aqueous shunt to extraocular reservoir (eg, molteno, 
schocket, denver-krupin) 
CPT-4 66183 insertion of anterior segment aqueous drainage device, 
without extraocular reservoir, external approach 
CPT-4 66185 revision of aqueous shunt to extraocular reservoir 
CPT-4 66710 ciliary body destruction cyclophotocoagulation, 
transscleral 
CPT-4 66711 ciliary body destruction cyclophotocoagulation, 
endoscopic 
CPT-4 0191T insertion of anterior segment aqueous drainage device, 
without extraocular reservoir 
CPT-4 65855 trabeculoplasty by laser surgery, 1 or more sessions 
(defined treatment series) 
ICD-9-CM 
Procedure 
1261 trephination of sclera with iridectomy 
ICD-9-CM 
Procedure 
1264 trabeculectomy ab externo 
ICD-9-CM 
Procedure 
1265 other scleral fistulization with iridectomy 
  ICD-9-CM 
Procedure 
1267 insertion of aqueous drainage device 






Cataract surgery CPT-4 66840 removal of lens material 
  CPT-4 66850 removal of lens material phacofragmentation technique 
(mechanical or ultrasonic) (eg, phacoemulsification), 
with aspiration 
  CPT-4 66920 removal of lens material intracapsular 
  CPT-4 66940 removal of lens material extracapsular (other than 
66840, 66850, 66852) 
  CPT-4 66983 intracapsular cataract extraction with insertion of 
intraocular lens prosthesis (1 stage procedure) 
  CPT-4 66984 extracapsular cataract removal with insertion of 
intraocular lens prosthesis (1 stage procedure), manual 




  ICD-9-CM 
Procedure 
132 extracapsular extraction of lens by linear extraction 
technique 
  ICD-9-CM 
Procedure 
133 extracapsular extraction of lens by simple aspiration 
(and irrigation) technique 
  ICD-9-CM 
Procedure 
1341 phacoemulsification and aspiration of cataract 
  ICD-9-CM 
Procedure 
1343 mechanical phacofragmentation and other aspiration of 
cataract 
  ICD-9-CM 
Procedure 
1359 other extracapsular extraction of lens 
  ICD-9-CM 
Procedure 
1369 other cataract extraction 
Other glaucoma-related 
diagnoses (for exclusion when 
defining cases & controls)  
ICD-9 CM 
Diagnosis 
365.02 anatomical narrow angle borderline glaucoma 
  ICD-9 CM 
Diagnosis 
365.06 primary angle closure without glaucoma damage 
  ICD-9 CM 
Diagnosis 
365.13 pigmentary open-angle glaucoma 
  ICD-9 CM 
Diagnosis 
365.14 glaucoma of childhood 
  ICD-9 CM 
Diagnosis 
365.2 primary angle-closure glaucoma 
  ICD-9 CM 
Diagnosis 
365.3 corticosteroid-induced glaucoma 
  ICD-9 CM 
Diagnosis 
365.4 glaucoma associated with congenital anomalies 
dystrophies and systemic syndromes  
  ICD-9 CM 
Diagnosis 
365.5 glaucoma associated with disorders of the lens  
  ICD-9 CM 
Diagnosis 
365.6 glaucoma associated with other ocular disorders 
  ICD-9 CM 
Diagnosis 
365.81 hypersecretion glaucoma 
  ICD-9 CM 
Diagnosis 
365.82 glaucoma with increased episcleral venous pressure 
  ICD-9 CM 
Diagnosis 
365.83 aqueous misdirection 
Non-routine cataract surgery (for 
exclusion when defining 
controls) 
CPT-4 66830 removal of secondary membranous cataract (opacified 
posterior lens capsule and/or anterior hyaloid) with 
corneo-scleral section, with or without iridectomy 
(iridocapsulotomy, iridocapsulectomy) 
  CPT-4 66852 removal of lens material pars plana approach, with or 
without vitrectomy 
  CPT-4 66930 removal of lens material intracapsular, for dislocated 
lens 
  CPT-4 66982 extracapsular cataract removal with insertion of 
intraocular lens prosthesis (1-stage procedure), manual 
or mechanical technique (eg, irrigation and aspiration or 
phacoemulsification), complex, requiring devices or 
techniques not generally used in routine cataract 
surgery (eg, iris expansion device, suture support for 
intraocular lens, or primary posterior capsulorrhexis) or 
performed on patients in the amblyogenic 
developmental stage 
Ophthalmic related conditions 






disorders of the eye and adnexa 
 CPT-4 65091-
68899 







Table S2:  The Uniform System of Classification (USC) codes and generic names used to 
identify glaucoma medications and other ophthalmic medications at National Drug Code 
(NDC) level. 
Indication USC_Classification Generic_Name 
Glaucoma 
medication 
61610 - PILOCARPINE PILOCARPINE NITRATE,PILOCARPINE HCL 
61630 - GLAUCOMA-
EPINEPHRINE & DERIVATIVES 
EPINEPHRINE,DIPIVEFRIN HCL,EPINEPHRYL BORATE 
61640 - PILOCARPINE 
COMBINATIONS 
PILOCARPINE HCL/EPINEPHRINE BITARTRATE 










61690 - MIOTICS & GLAUCOMA 
OTHERS 























FLOXACIN HCL,CYSTEAMINE HCL,TOBRAMYCIN 
SULFATE 






61130 - OPHTHALMIC ANTI-VIRAL 
IDOXURIDINE,VIDARABINE,TRIFLURIDINE,GANCICLOVI
R,FOMIVIRSEN SODIUM 
61140 - OPHTHALMIC 
NEO/POLY/BAC COMBINATIONS 
NEOMYCIN SULFATE/POLYMYXIN B 
SULFATE/GRAMICIDIN D,NEOMYCIN 
SULFATE/POLYMYXIN B SULFATE,NEOMYCIN 
SULFATE/BACITRACIN/POLYMYXIN 
B,BACITRACIN/POLYMYXIN B SULFATE,NEOMYCIN 
SULFATE/BACITRACIN/COLISTIMETHATE SODIUM 




61410 - OPHTHALMIC 
GLUCOCORTICOIDS 
LOTEPREDNOL ETABONATE 





DNISOLONE SOD PHOSPHATE,FLUOROMETHOLONE 
ACETATE,TRIAMCINOLONE 
ACETONIDE/PF,RIMEXOLONE,DIFLUPREDNATE,LOTEP
REDNOL ETABONATE,FLUOCINOLONE ACETONIDE 
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61412 - OPHTHALMICCORTICOID 
WITH ANTI-INFECTIVE 
NEOMYCIN SULFATE/DEXAMETHASONE SOD 






















61420 - OPHTHALMIC NSAIDS 
KETOROLAC TROMETHAMINE,KETOROLAC 
TROMETHAMINE/PF,NEPAFENAC,SUPROFEN,DICLOFE
NAC SODIUM,BROMFENAC SODIUM,FLURBIPROFEN 
SODIUM 
61490 - OPHTHALMIC ANTI-
INFLAMMATORY OTHER 
CYCLOSPORINE 


















SULFATE,NAPHAZOLINE HCL/POLYETHYLENE GLYCOL 
300,NAPHAZOLINE 
HCL/HYPROMELLOSE,TETRAHYDROZOLINE 








SULFATE,NAPHAZOLINE HCL/ZINC SULFATE/GLYCERIN 





61710 - OPHTHALMIC 
ANESTHETICS 




61740 - OPHTHALMIC 
IRRIGATING SOLUTION 
BORIC ACID,BALANCED SALT IRRIGATION SOLUTION 
COMBINATION NO.1,BALANCED SALT IRRIG SOLN 
NO.2,SODIUM/POTASSIUM/SODIUM 
CHLORIDE,SODIUM/POTASSIUM/CALCIUM/MAGNESIUM,





WASH AND EYE CUP,SODIUM CHLORIDE,BORIC 
ACID/IRRIG SOLN NON-SURG 
#1,SODIUM/POTASSIUM/CALCIUM/MAGNESIUM/DEXTR
OSE,BALANCED SALT SOLN NON-SURG #6,SODIUM 
PHOSPHATEMONOBASIC/SODIUM CHLORIDE/EYE 
CUP,POTASSIUM CHLORIDE/BORIC ACID 
61760 - OPHTHALMIC ENZYMES CHYMOTRYPSIN 











SULFATE A SODIUM/HYALURONATE SODIUM,ZINC 
SULFATE/MERCURIC OXIDEYELLOW/BORIC 
ACID,EYELID CLEANSER COMBINATION NO.5,EYELID 
CLEANSER COMBINATION NO.8,EYELID CLEANSER 
COMBINATION NO.7,EYELID CLEANSER COMBINATION 
NO.3,HYPOCHLORUS ACID/SODIUM 
HYPOCHLORITE/SOD CHLOR/ ELEC. 
WATER,HYPOCHLORUS ACID/NA 








ACID/SODIUM CHLORIDE,SOAP,EYELID CLEANSER 
COMBINATION #1,OFTASCEINE DISODIUM/BENOXINATE 
HCL,,AFLIBERCEPT,PHENYLEPHRINE HCL/KETOROLAC 






Table S3:  Patient flow for cases and controls 
Study Population Inclusion/exclusion criteria Sample Size 
Cases 
Include patients with at least 1 non-rule out diagnosis and 
procedure for POAG on the same day during the identification 
period: 1/1/2012-12/31/2013 
46,954 
Include patients continuously enrolled in medical and 
pharmacy benefit in the entire study period: between 5 years 
prior to index date and 1 year after index date 
12,429 
Include patients >= 45 years old at index date 12,237 
Exclude patients with other types of glaucoma in the entire 
study period  
9,403 
Exclude patients with glaucoma surgery in the 5 years prior to 
the index date 
6,272 
 




Include patients with at least 1 non-rule out diagnosis and 
procedure for cataract on the same day during the identification 
period: 1/1/2012-12/31/2013 
453,678 
Include patients continuously enrolled in medical and 
pharmacy benefit in the entire study period: between 5 years 
prior to index date and 1 year after index date 
114,792 
Include patients >= 45 years old at index date 113,984 
Exclude patients with other forms of cataract surgery in the 
entire study period 
106,852 
Exclude patients with all types of glaucoma diagnosis codes, or 
glaucoma surgery procedure codes, or taking glaucoma 
medication in the entire study period 
75,189 
 







Table S4:  Patient comorbidity and drug utilization characteristics. 
Patient Disease and Drug Utilization Case Contrl Standardized 
Difference    N/Mean Percent/SD N/Mean Percent/SD 
Carriers of Elixhauser comorbidity9 (N/Percent)           
1-Congestive Heart Failure 780 12.7% 3,774 12.3% 0.0124 
2-Cardiac Arrhythmias 1,685 27.5% 8,492 27.7% -0.0049 
3-Valvular Disease 1,295 21.1% 5,867 19.1% 0.0495 
4-Pulmonary Circulation Disorders 228 3.7% 1,266 4.1% -0.0212 
5-Peripheral Vascular Disorders 1,300 21.2% 5,911 19.3% 0.0478 
6-Hypertension Uncomplicated 4,588 74.8% 22,022 71.8% 0.0678 
7-Hypertension Complicated 815 13.3% 3,358 11.0% 0.0717 
8-Paralysis 70 1.1% 363 1.2% -0.004 
9-Other Neurological Disorders 465 7.6% 2,267 7.4% 0.0072 
10-Chronic pulmonary disease 1,721 28.1% 8,848 28.9% -0.0176 
11-Diabetes Uncomplicated 2,049 33.4% 9,090 29.7% 0.0812 
12-Diabetes Complicated 869 14.2% 3,795 12.4% 0.0529 
13-Hypothyroidism 1,270 20.7% 6,048 19.7% 0.0245 
14-Renal Failure 624 10.2% 2,790 9.1% 0.0365 
15-Liver Disease 487 7.9% 2,228 7.3% 0.0255 
16-Peptic Ulcer Disease 128 2.1% 681 2.2% -0.0092 
17-AIDS/HIV 8 0.1% 20 0.1% 0.0209 
18-Lymphoma 71 1.2% 506 1.7% -0.0419 
19-Metastatic Cancer 106 1.7% 534 1.7% -0.001 
20-Solid Tumor without Metastasis 981 16.0% 4,801 15.7% 0.0093 
21-Reheumatoid Arthritis/Collagne Vascular Diseases 582 9.5% 2,650 8.6% 0.0295 
22-Coagulopathy 262 4.3% 1,253 4.1% 0.0093 
23-Obesity 489 8.0% 2,512 8.2% -0.008 
24-Weight Loss 316 5.2% 1,577 5.1% 0.0004 
25-Fluid and Electrolyte Disorders 862 14.1% 4,360 14.2% -0.0047 
26-Blood Loss Anemia 131 2.1% 596 1.9% 0.0136 
27-Deficiency Anemia 567 9.2% 2,752 9.0% 0.0094 
28-Alcohol Abuse 74 1.2% 480 1.6% -0.0307 
29-Drug Abuse 67 1.1% 319 1.0% 0.0051 
30-Psychoses 152 2.5% 737 2.4% 0.0049 
31-Depression 778 12.7% 4,321 14.1% -0.0413 
Total Elixhauser Groups per patient (mean/SD) 4 2.9 4 2.8 0.0554 
 (median/interquantile range) 3 3 3 3   
# of pharmacy claims (mean/SD) 115 20.5 121 20.6 -0.0688 
 (median/interquantile range) 92 107 98 111   
# of generic names (mean/SD) 18 11.4 18 11.3 -0.0128 
# of generic names (median/interquantile range) 16 14 16 14   
# of NDC (mean/SD) 30 9.2 30 9.2 -0.018 
# of NDC (median/interquantile range) 25 25 26 25   
# of USC (mean/SD) 16 95.9 16 102.0 -0.0185 
# of USC (median/interquantile range) 14 12 15 12   
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Table S5:  Results for associations between all USC drug classes and POAG 
USC class Odds ratio (95% CI) P-value 
 SSRI (SEL. SEROTONIN REUPTAKE INHIBITOR) 0.70 (0.64 - 0.76) 1.04E-15 
 BETA BLOCKERS 0.77 (0.72 - 0.83) 2.71E-14 
 CALCIUM CHANNEL BLOCKERS 1.26 (1.18 - 1.35) 1.78E-11 
 SEXUAL FUNCTION DISORDERS 1.39 (1.22 - 1.58) 4.93E-07 
 SNRI (SEROTONIN/NOREPI REUPTAKE INHIBIT) 0.71 (0.61 - 0.82) 2.31E-06 
 FIBRIC ACID DERIVATIVES 0.74 (0.65 - 0.84) 2.55E-06 
 ANGIOTENSIN II ANTAGONIST ALONE 1.19 (1.10 - 1.28) 1.78E-05 
 BENIGN PROSTATE HYPERTROPHY (BPH) 1.24 (1.12 - 1.37) 3.63E-05 
 ANTICHOLINERGICS BRONCHIAL 0.70 (0.59 - 0.83) 6.36E-05 
 VITAMIN K ANTAGONISTS 0.80 (0.72 - 0.89) 7.12E-05 
 DIPEPTIDYL PEPTIDASE-4 INHIBITOR ALONE 1.33 (1.15 - 1.53) 7.25E-05 
 ANGIOTENSIN II ANTAGONIST WITH CCB 1.52 (1.23 - 1.89) 1.30E-04 
 VITAMIN D 1.30 (1.14 - 1.49) 1.39E-04 
 BENZODIAZEPINES 0.82 (0.74 - 0.91) 1.55E-04 
 ANTICHOLINERGICS BRONCHIAL COMBINATION 0.63 (0.49 - 0.82) 4.58E-04 
 ANGIOTENSIN II ANTAGONISTWITH DIURETIC 1.17 (1.07 - 1.28) 6.26E-04 
 ALZHEIMER-TYPE DEMENTIA 1.33 (1.12 - 1.58) 1.32E-03 
MORPHINE AND OPIUM NON-INJECTABLE 0.60 (0.44 - 0.82) 1.53E-03 
 BETA AGONISTS AEROSOLS 0.82 (0.72 - 0.93) 2.18E-03 
 DIURETICS COMBINATIONS 1.19 (1.06 - 1.33) 2.43E-03 
 GLINIDES ALONE 1.55 (1.15 - 2.09) 4.21E-03 
 CENTRALLY ACTING AGENTS ALONE OR COMBOS 1.28 (1.08 - 1.51) 4.36E-03 
 NEWER GENERATION ANTI-DEPRESSANTS 0.82 (0.71 - 0.94) 5.59E-03 
 ANTIHYPERTENSIVEOTHER 1.35 (1.09 - 1.67) 5.86E-03 
 DIURETICS THIAZIDE AND RELATED 1.12 (1.03 - 1.21) 6.94E-03 
 PRE-X-RAY EVACUANTS 5.12 (1.46 - 17.94) 1.06E-02 
 AMINOPENICILLINS 1.72 (1.13 - 2.62) 1.10E-02 
 ANTI-FUNGAL AGENTS MISCELLANEOUS 1.61 (1.12 - 2.34) 1.11E-02 
 NON-BARBITURATE SEDATIVES OTHER 0.87 (0.78 - 0.97) 1.35E-02 
 NARCOTIC COUGH/ANTIHISTAMINE 1.59 (1.10 - 2.29) 1.41E-02 
 EMOLLIENTS AND PROTECTIVES 1.55 (1.08 - 2.22) 1.87E-02 
 HORMONESANDROGENSTRANSDERMAL 1.34 (1.05 - 1.72) 1.98E-02 
 CHOLESTEROL REDUCER COMBINATIONS 0.86 (0.75 - 0.98) 2.03E-02 
 HERPES ANTIVIRALS 1.28 (1.04 - 1.57) 2.11E-02 
 CEPHALOSPORINS & RELATED 0.60 (0.39 - 0.94) 2.55E-02 
 SMOKING DETERRENTS 0.67 (0.47 - 0.95) 2.69E-02 
 BIGUANIDES ALONE 1.09 (1.01 - 1.19) 2.74E-02 
 PROTON PUMP INHIBITORS 0.92 (0.86 - 0.99) 2.85E-02 
ANTIARTHRITICSSYSTEMIC COX-2 INHIBITORS 0.86 (0.75 - 0.98) 2.94E-02 
 HORMONES GLUCOCORTICOIDS PLAINORAL 0.84 (0.72 - 0.98) 2.95E-02 
CODEINE AND COMBINATIONS NON-INJECTABLE 0.87 (0.77 - 0.99) 3.02E-02 
 EXTENDED SPECTRUM MACROLIDES 1.55 (1.04 - 2.33) 3.25E-02 
 ANTI-FUNGAL AGENTS ALLYLAMINES 1.49 (1.03 - 2.15) 3.29E-02 
 ANTIDEPRESSANT-TRICYCLICS &TETRACYCLICS 0.85 (0.73 - 0.99) 3.35E-02 
 HORMONESCORTICOIDS 
PLAINDERMATOLOGICAL 1.14 (1.01 - 1.28) 3.38E-02 
NON-NARCOTIC ANALGESSALICYLATES/RELATED 1.50 (1.03 - 2.20) 3.66E-02 
 ADENOSINE RECEPTOR ANTAG ALONE/COMB 0.90 (0.82 - 1.00) 4.26E-02 
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 ANTI-ARRHYTHMIA AGENTS 0.85 (0.72 - 1.00) 4.36E-02 
 DIRECT RENIN INHIBITORS ALONE 1.35 (1.00 - 1.82) 4.83E-02 
 ANTI-PARKINSON'S OTHERS 0.82 (0.68 - 1.00) 5.46E-02 
 HUMAN INSULIN ANALOG COMBINATIONS 1.30 (0.99 - 1.71) 5.87E-02 
 HUMAN INSULIN ANALOG LONG ACTING 1.13 (0.99 - 1.28) 6.19E-02 
 SULFONYLUREAS 1.10 (1.00 - 1.20) 6.21E-02 
 GLITAZONES ALONE 1.12 (0.99 - 1.27) 6.26E-02 
 GABA (GAMMA-AMINOBUTYRIC ACID) ANALOGS 0.83 (0.68 - 1.01) 6.46E-02 
 GASTROINTESTINAL STIMULANTS 0.75 (0.55 - 1.02) 6.79E-02 
 THYROID HORMONE SYNTHETIC 0.93 (0.86 - 1.01) 7.55E-02 
 ANTIDIARRHEALS WITHOUT ANTI-INFECTIVES 0.67 (0.43 - 1.05) 7.76E-02 
PROPOXYPHENES 0.82 (0.66 - 1.03) 8.44E-02 
 DPP-4 INHIBITOR/BIGUANIDE COMBINATION 1.23 (0.97 - 1.56) 8.67E-02 
ANTIARTHRITICS SYSTEMIC PLAIN 1.08 (0.99 - 1.18) 8.76E-02 
 ANTICOAGULANTS FRACTIONATED HEPARINS 0.17 (0.02 - 1.30) 8.84E-02 
 ANTISEPTICS STOMATOLOGICAL 1.38 (0.95 - 2.01) 8.84E-02 
 ACE INHIBITORS OTHER 1.13 (0.98 - 1.31) 9.27E-02 
 STEROIDSINHALED BRONCHIAL COMBINATION 0.90 (0.80 - 1.02) 9.41E-02 
 POSITIVE INOTROPIC AGENTS 0.87 (0.74 - 1.03) 1.03E-01 
 ACNE WITHOUT ANTI-INFECTIVES/ANTISEPTIC 1.55 (0.91 - 2.64) 1.06E-01 
 CYCLOPLEGICS 2.18 (0.83 - 5.71) 1.13E-01 
 SULFONAMIDE-TRIMETHOPRIM COMBINATIONS 0.75 (0.52 - 1.07) 1.15E-01 
 NARCOTIC COUGH/DECONGEST/ANTIHISTAMINE 2.82 (0.76 - 10.53) 1.22E-01 
 H2 ANTAGONISTS 0.89 (0.76 - 1.03) 1.24E-01 
SEROTONIN 5HT-1 RECEPTOR AGONISTS 0.79 (0.59 - 1.07) 1.31E-01 
 ANTIDOPA PHENOTHIAZINE 0.69 (0.43 - 1.12) 1.32E-01 
 ANTINEOPLASTIC FOLIC ACID ANALOGS 0.81 (0.62 - 1.07) 1.34E-01 
 URINARY TRACT ANTISPASMODICS 0.91 (0.80 - 1.03) 1.34E-01 
 ANTI-ULCERANTS OTHER 0.77 (0.55 - 1.09) 1.42E-01 
 CORTICOIDS IN COMBINATIONDERMATOLOGICAL 1.51 (0.86 - 2.64) 1.49E-01 
 NITRITES & NITRATES 0.90 (0.78 - 1.04) 1.49E-01 
 DIURETICS LOOP 0.93 (0.85 - 1.03) 1.53E-01 
 SEIZURE DISORDERS 0.93 (0.84 - 1.03) 1.55E-01 
 ANTI-FUNGAL AGENTS IMIDAZOLES 1.19 (0.94 - 1.51) 1.56E-01 
 VASCULAR/ANTIHYPERLIPIDEMIC COMBINATION 1.22 (0.92 - 1.60) 1.62E-01 
 BETA/ALPHA-BETA BLOCKER WITH DIURETICS 0.86 (0.69 - 1.07) 1.71E-01 
 HMG-COA REDUCTASE INHIBITORS 0.96 (0.90 - 1.02) 1.83E-01 
 ALPHA BLOCKERS ALONE OR COMBINATIONS 0.91 (0.78 - 1.05) 2.02E-01 
 MENOPAUSE - ESTROGEN ALONE 0.93 (0.83 - 1.04) 2.16E-01 
 ANTIHISTAMINES ALONE 1.08 (0.96 - 1.22) 2.18E-01 
 HEMATINICS OTHERS 0.88 (0.72 - 1.08) 2.25E-01 
 CRUDE/BULK MEDICINAL 1.23 (0.88 - 1.72) 2.25E-01 
 NON-NARCOTIC 
COUGH/DECONGEST/ANTIHISTAMN 5.55 (0.35 - 88.80) 2.26E-01 
 ACNE WITH ANTI-INFECTIVES/ANTISEPTIC 1.22 (0.88 - 1.69) 2.34E-01 
 BETA AGONISTS NEBULIZER SOLUTIONS 0.83 (0.62 - 1.13) 2.35E-01 
 UT ANTI-INFECTIVE/ANALGESIC COMBINATIONS 0.60 (0.26 - 1.40) 2.37E-01 
 QUINOLONES SYSTEMIC 0.85 (0.65 - 1.11) 2.38E-01 
NON-NARCOTIC ANALGESICSSYNTHETIC PATCH 1.19 (0.89 - 1.61) 2.41E-01 
ANTIARTHRITICS TOPICAL 1.24 (0.86 - 1.81) 2.51E-01 
 OTIC ANTI-INFECTIVES WITH GLUCOCORTICOID 1.46 (0.75 - 2.83) 2.63E-01 
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 GI ANTISPASMODICS BELLADONNA 0.81 (0.56 - 1.17) 2.65E-01 
 DIRECT THROMBIN INHIBITORS 0.86 (0.65 - 1.13) 2.75E-01 
ANTIARTHRITICS GOUT SPECIFIC 0.93 (0.82 - 1.06) 2.75E-01 
 ACE INHIBITORS ALONE 0.97 (0.91 - 1.03) 2.86E-01 
 LEUKOTRIENE AGENTS 0.93 (0.80 - 1.07) 2.95E-01 
 ANTI-FUNGAL AGENTS TRIAZOLES 0.78 (0.48 - 1.25) 3.00E-01 
 CHOLESTEROL ABSORPTION INHIBITORS 0.93 (0.82 - 1.07) 3.14E-01 
 ANTI-FUNGAL AGENTS POLYENES 1.22 (0.82 - 1.81) 3.28E-01 
ANESTHETICS LOCAL AND TOPICAL OTHER 1.33 (0.74 - 2.39) 3.33E-01 
 ANTIHISTAMINE 1.19 (0.84 - 1.68) 3.34E-01 
 NON-NARCOTIC COUGH ALONE 1.31 (0.74 - 2.33) 3.48E-01 
 ANTIHYPERLIPIDEMIC AGENTS OTHER 0.94 (0.81 - 1.08) 3.50E-01 
 PENICILLIN NATURAL 0.38 (0.05 - 3.21) 3.74E-01 
 HORMONESPROGESTOGENORAL 0.87 (0.63 - 1.19) 3.77E-01 
 STEROIDSINHALED BRONCHIAL 0.91 (0.75 - 1.12) 3.78E-01 
 NARCOTIC COUGH COMB WITHOUT EXPECT 
OTHER 0.52 (0.12 - 2.24) 3.82E-01 
 FLUORIDE SUPPLEMENTS 1.17 (0.81 - 1.71) 3.97E-01 
 BILE ACID SEQUESTRANTS 1.10 (0.88 - 1.36) 4.05E-01 
 NARCOTIC COUGH/EXPECTORANT 1.43 (0.62 - 3.33) 4.06E-01 
 CALCITONINS 1.13 (0.80 - 1.59) 4.79E-01 
 GI ANTISPASMODICS SYNTHETICS 1.12 (0.82 - 1.51) 4.81E-01 
 ANTIANXIETY OTHERS 0.92 (0.73 - 1.17) 5.05E-01 
NON-NARCOTIC ANALGESICSSYNTHNON-INJECT 0.84 (0.50 - 1.42) 5.21E-01 
 MACROLIDES AND RELATED OTHERS 0.68 (0.20 - 2.26) 5.26E-01 
 HYPEROSMOLAR LAXATIVES 0.91 (0.68 - 1.22) 5.33E-01 
 NON-DRUG PRODUCTS 0.96 (0.84 - 1.09) 5.42E-01 
 OTIC ANTI-INFECTIVES PLAIN 1.98 (0.20 - 19.35) 5.55E-01 
 ANTIPSYCHOTICS OTHERS 0.94 (0.75 - 1.17) 5.61E-01 
 ANTICHOLINERGICS NASAL PLAIN 1.12 (0.75 - 1.68) 5.70E-01 
NON-NARCOTIC ANALGESICS COMBINATIONS 0.85 (0.49 - 1.48) 5.72E-01 
TRICHOMONACIDES/ANTIBACTERIALS 0.74 (0.25 - 2.17) 5.78E-01 
 ERYTHROMYCIN 1.35 (0.44 - 4.11) 5.99E-01 
 BETA-LACTAMS INCREASED ACTIVITY 1.16 (0.66 - 2.03) 6.00E-01 
ANTIARTHRITICS SYSTEMIC W/GI PROTECTANT 0.90 (0.62 - 1.32) 6.00E-01 
 CARDIAC AGENTS OTHERS 0.91 (0.64 - 1.29) 6.02E-01 
 ANTI-PARKINSON'S LEVODOPA 0.93 (0.69 - 1.24) 6.07E-01 
 HUMAN GLP-1 ANALOGS 0.94 (0.74 - 1.20) 6.09E-01 
 STEROIDSINHALED NASAL 0.98 (0.89 - 1.07) 6.14E-01 
 PYRIMIDINE ANALOGS 1.17 (0.62 - 2.19) 6.32E-01 
 TETRACYCLINE AND CONGENERS 0.95 (0.77 - 1.18) 6.36E-01 
 POTASSIUM CHLORIDE SUPPLEMENT 0.98 (0.88 - 1.08) 6.44E-01 
 BIGUANIDES/SULFONYLUREA COMBINATION 1.06 (0.83 - 1.36) 6.48E-01 
 HUMAN INSULIN ANALOG FAST ACTING 1.04 (0.88 - 1.23) 6.61E-01 
 BONE DENSITY REGULATORS OTHER 1.05 (0.85 - 1.28) 6.65E-01 
 HEMORRHOIDAL PREPS WITH CORTICOIDS 1.09 (0.72 - 1.64) 6.97E-01 
 AROMATASE INHIBITORS 0.95 (0.74 - 1.23) 7.02E-01 
 BISPHOSPHONATES 1.02 (0.93 - 1.12) 7.05E-01 
 URINARY TRACT ANTI-INFECTIVE OTHER 1.05 (0.79 - 1.40) 7.23E-01 
 ALPHA-BETA BLOCKERS 0.98 (0.87 - 1.10) 7.32E-01 
 GASTROINTESTINAL ANTI-INFLAMMATORY 1.04 (0.80 - 1.36) 7.50E-01 
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 ANTI-FUNGAL AGENTS COMBINATIONS 0.96 (0.71 - 1.29) 7.75E-01 
 ANTICHOLINERGIC OTHER 1.14 (0.43 - 3.01) 7.86E-01 
 EXPECTORANTS/DECONGESTANTS 1.16 (0.39 - 3.42) 7.90E-01 
 ANTIHISTAMINES/DECONGESTANTS 1.04 (0.75 - 1.45) 7.96E-01 
 ANTINEOPLASTIC PROGESTINS 0.93 (0.55 - 1.59) 7.99E-01 
 TRIAZOLES (VAGINAL ONLY) 0.76 (0.09 - 6.25) 8.01E-01 
 ANTIMALARIALS 0.97 (0.73 - 1.28) 8.20E-01 
 HEMOSTATIC MODIFIERS OTHERS 1.03 (0.77 - 1.38) 8.24E-01 
 DERMATOLOGICAL PREPARATIONS OTHER 0.96 (0.66 - 1.41) 8.34E-01 
 HORMONES GLUCOCORTICOIDS PLAIN OTHER 0.88 (0.26 - 3.00) 8.36E-01 
NARCOTICS ANALGESICSYNTHETICNON-INJECT 0.99 (0.86 - 1.13) 8.49E-01 
 GLITAZONE/BIGUANIDE COMBINATION 1.02 (0.76 - 1.37) 8.87E-01 
 VITAMIN B-12 PREPARATIONS 0.98 (0.68 - 1.40) 9.00E-01 
 DIURETICS POTASSIUM SPARING 0.99 (0.82 - 1.19) 9.16E-01 
 MUSCLE RELAXANTSNON-SURG W/O ANALGESIC 0.99 (0.87 - 1.14) 9.34E-01 
 ANTINAUSEANT 5HT3 ANTAGONISTS 1.04 (0.43 - 2.49) 9.34E-01 
 MISCELLANEOUS DRUGS OTHER 0.99 (0.66 - 1.47) 9.45E-01 
 ACE INHIBITORS WITH DIURETICS 1.00 (0.89 - 1.12) 9.57E-01 
 MENOPAUSE - ESTROGEN WITH PROGESTIN 0.99 (0.76 - 1.30) 9.65E-01 
 DERM ANTI-INFECTIVENON-SYSTEMICTOPICAL 1.00 (0.76 - 1.32) 9.88E-01 





Table S6:  Results for associations between all individual generic drugs and POAG 
Generic drug name 
Odds ratio 
(95% CI) P-value 
AMLODIPINE BESYLATE 1.27 (1.18 - 1.37) 5.92E-10 
CITALOPRAM HYDROBROMIDE 0.66 (0.57 - 0.77) 1.18E-07 
ESOMEPRAZOLE MAGNESIUM 0.81 (0.73 - 0.89) 1.59E-05 
TAMSULOSIN HCL 1.29 (1.15 - 1.44) 1.93E-05 
TADALAFIL 1.57 (1.27 - 1.95) 2.58E-05 
LORAZEPAM 0.68 (0.56 - 0.82) 4.30E-05 
METOPROLOL SUCCINATE 0.84 (0.77 - 0.91) 4.42E-05 
TIOTROPIUM BROMIDE 0.69 (0.57 - 0.82) 5.81E-05 
WARFARIN SODIUM 0.80 (0.72 - 0.89) 7.12E-05 
ATENOLOL 0.81 (0.72 - 0.90) 7.98E-05 
FENOFIBRATE NANOCRYSTALLIZED 0.72 (0.61 - 0.85) 8.46E-05 
SILDENAFIL CITRATE 1.37 (1.17 - 1.62) 1.47E-04 
SITAGLIPTIN PHOSPHATE 1.32 (1.13 - 1.53) 3.10E-04 
AMLODIPINE BESYLATE/VALSARTAN 1.62 (1.24 - 2.11) 3.84E-04 
PROPRANOLOL HCL 0.60 (0.46 - 0.80) 4.30E-04 
IPRATROPIUM BROMIDE/ALBUTEROL SULFATE 0.63 (0.49 - 0.82) 4.58E-04 
DULOXETINE HCL 0.71 (0.59 - 0.86) 5.32E-04 
ERGOCALCIFEROL (VITAMIN D2) 1.29 (1.12 - 1.50) 5.65E-04 
FLUOXETINE HCL 0.72 (0.60 - 0.87) 7.17E-04 
LANCETS 1.33 (1.13 - 1.57) 7.83E-04 
HYDRALAZINE HCL 1.45 (1.17 - 1.81) 7.98E-04 
FENOFIBRATE 0.63 (0.47 - 0.83) 1.22E-03 
ESCITALOPRAM OXALATE 0.75 (0.63 - 0.90) 1.98E-03 
FENTANYL 0.46 (0.28 - 0.75) 2.04E-03 
OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE 1.33 (1.10 - 1.60) 2.82E-03 
AZELASTINE HCL 1.43 (1.13 - 1.80) 3.10E-03 
VENLAFAXINE HCL 0.73 (0.59 - 0.90) 3.25E-03 
NIFEDIPINE 1.32 (1.09 - 1.59) 4.17E-03 
OLMESARTAN MEDOXOMIL 1.28 (1.07 - 1.52) 5.61E-03 
ALBUTEROL SULFATE 0.83 (0.73 - 0.95) 5.61E-03 
DONEPEZIL HCL 1.33 (1.08 - 1.64) 6.20E-03 
NAFTIFINE HCL 3.19 (1.39 - 7.33) 6.30E-03 
SERTRALINE HCL 0.81 (0.70 - 0.94) 6.32E-03 
BUPROPION HCL 0.78 (0.65 - 0.93) 6.68E-03 
CICLOPIROX 1.78 (1.17 - 2.70) 7.32E-03 
TERAZOSIN HCL 0.73 (0.57 - 0.92) 7.39E-03 
CHLORTHALIDONE 1.50 (1.11 - 2.04) 8.25E-03 
EZETIMIBE/SIMVASTATIN 0.83 (0.73 - 0.96) 9.54E-03 
MEMANTINE HCL 1.40 (1.08 - 1.82) 1.24E-02 
PAROXETINE HCL 0.76 (0.62 - 0.94) 1.26E-02 
AMIODARONE HCL 0.74 (0.58 - 0.94) 1.32E-02 
INSULIN ASPART PROTAMINE HUMAN/INSULIN ASPART 1.51 (1.08 - 2.12) 1.54E-02 
CLONIDINE HCL 1.25 (1.04 - 1.50) 1.62E-02 
PROMETHAZINE HCL/CODEINE 2.10 (1.15 - 3.84) 1.63E-02 
CETIRIZINE HCL 0.64 (0.45 - 0.93) 1.76E-02 
METOPROLOL TARTRATE 0.89 (0.80 - 0.98) 1.90E-02 
ROPINIROLE HCL 0.72 (0.54 - 0.95) 1.90E-02 
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CLARITHROMYCIN 2.40 (1.15 - 4.99) 1.92E-02 
RAMIPRIL 0.82 (0.69 - 0.97) 1.95E-02 
OXYCODONE HCL/ACETAMINOPHEN 0.71 (0.54 - 0.95) 1.96E-02 
LOSARTAN POTASSIUM 1.14 (1.02 - 1.26) 2.10E-02 
LOVASTATIN 0.83 (0.71 - 0.97) 2.32E-02 
FINASTERIDE 1.21 (1.03 - 1.43) 2.39E-02 
RISEDRONATE SODIUM 1.23 (1.03 - 1.46) 2.45E-02 
FAMCICLOVIR 2.65 (1.13 - 6.21) 2.54E-02 
METFORMIN HCL 1.09 (1.01 - 1.19) 2.74E-02 
VARENICLINE TARTRATE 0.66 (0.45 - 0.96) 2.87E-02 
CELECOXIB 0.86 (0.75 - 0.98) 2.94E-02 
BUDESONIDE/FORMOTEROL FUMARATE 0.75 (0.57 - 0.97) 2.97E-02 
PIOGLITAZONE HCL 1.15 (1.01 - 1.31) 2.97E-02 
DEXAMETHASONE 0.32 (0.12 - 0.90) 3.01E-02 
CIPROFLOXACIN HCL/DEXAMETHASONE 4.12 (1.10 - 15.38) 3.51E-02 
AMOXICILLIN 1.62 (1.03 - 2.53) 3.55E-02 
QUINAPRIL HCL 1.24 (1.01 - 1.53) 4.31E-02 
FLUTICASONE FUROATE 1.55 (1.01 - 2.39) 4.62E-02 
ALISKIREN HEMIFUMARATE 1.35 (1.00 - 1.82) 4.83E-02 
ATORVASTATIN CALCIUM 0.93 (0.86 - 1.00) 4.85E-02 
GEMFIBROZIL 0.77 (0.59 - 1.00) 5.35E-02 
BUSPIRONE HCL 0.69 (0.47 - 1.01) 5.49E-02 
TESTOSTERONE 1.27 (0.99 - 1.61) 5.56E-02 
ALLOPURINOL 0.87 (0.75 - 1.00) 5.61E-02 
HYDROMORPHONE HCL 0.26 (0.06 - 1.08) 6.37E-02 
VALSARTAN/HYDROCHLOROTHIAZIDE 1.14 (0.99 - 1.31) 6.41E-02 
PREGABALIN 0.83 (0.68 - 1.01) 6.69E-02 
AMITRIPTYLINE HCL 0.81 (0.65 - 1.02) 6.78E-02 
METOCLOPRAMIDE HCL 0.75 (0.55 - 1.02) 6.79E-02 
HYOSCYAMINE SULFATE 0.66 (0.42 - 1.03) 6.81E-02 
TRIAMTERENE/HYDROCHLOROTHIAZIDE 1.12 (0.99 - 1.26) 6.85E-02 
HYDROCODONE POLISTIREX/CHLORPHENIRAMINE POLISTIREX 1.53 (0.96 - 2.44) 7.58E-02 
CLOPIDOGREL BISULFATE 0.91 (0.83 - 1.01) 7.63E-02 
LEVOTHYROXINE SODIUM 0.93 (0.86 - 1.01) 7.70E-02 
ZOLPIDEM TARTRATE 0.89 (0.79 - 1.01) 7.71E-02 
HYDROCODONE BITARTRATE/ACETAMINOPHEN 0.89 (0.79 - 1.01) 7.72E-02 
HYDROCHLOROTHIAZIDE 1.08 (0.99 - 1.17) 7.78E-02 
TOPIRAMATE 0.73 (0.51 - 1.04) 8.02E-02 
PREDNISONE 0.86 (0.73 - 1.02) 8.04E-02 
ACYCLOVIR 1.31 (0.97 - 1.78) 8.04E-02 
GLIMEPIRIDE 1.14 (0.98 - 1.32) 8.20E-02 
ACETAMINOPHEN WITH CODEINE PHOSPHATE 1.34 (0.96 - 1.86) 8.35E-02 
AMLODIPINE BESYLATE/BENAZEPRIL HCL 1.14 (0.98 - 1.32) 8.63E-02 
NEBIVOLOL HCL 1.20 (0.97 - 1.49) 8.65E-02 
PRAMIPEXOLE DI-HCL 0.76 (0.56 - 1.04) 9.08E-02 
ENALAPRIL MALEATE 0.85 (0.71 - 1.03) 9.21E-02 
INSULIN GLARGINEHUMAN RECOMBINANT ANALOG 1.13 (0.98 - 1.30) 9.25E-02 
FUROSEMIDE 0.92 (0.83 - 1.01) 9.51E-02 
NIACIN 0.86 (0.71 - 1.03) 9.74E-02 
DIGOXIN 0.87 (0.74 - 1.03) 1.03E-01 
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DESONIDE 1.43 (0.92 - 2.23) 1.11E-01 
SULFAMETHOXAZOLE/TRIMETHOPRIM 0.75 (0.52 - 1.07) 1.15E-01 
IBUPROFEN 1.17 (0.96 - 1.43) 1.17E-01 
CHLORHEXIDINE GLUCONATE 1.34 (0.92 - 1.96) 1.25E-01 
VALSARTAN 1.10 (0.97 - 1.25) 1.26E-01 
VALACYCLOVIR HCL 1.26 (0.93 - 1.71) 1.29E-01 
METHOTREXATE SODIUM 0.82 (0.62 - 1.07) 1.41E-01 
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN 0.85 (0.68 - 1.06) 1.41E-01 
ETODOLAC 0.73 (0.48 - 1.11) 1.45E-01 
IRBESARTAN 1.16 (0.95 - 1.42) 1.51E-01 
BLOOD SUGAR DIAGNOSTIC DRUM-TYPE 1.29 (0.91 - 1.83) 1.52E-01 
TIZANIDINE HCL 0.74 (0.48 - 1.12) 1.54E-01 
RANITIDINE HCL 0.87 (0.72 - 1.06) 1.60E-01 
VERAPAMIL HCL 1.14 (0.95 - 1.38) 1.60E-01 
AMLODIPINE BESYLATE/ATORVASTATIN CALCIUM 1.22 (0.92 - 1.60) 1.62E-01 
DIPHENOXYLATE HCL/ATROPINE SULFATE 0.71 (0.45 - 1.14) 1.62E-01 
PEN NEEDLE DIABETIC 1.11 (0.96 - 1.29) 1.67E-01 
ALPRAZOLAM 0.91 (0.80 - 1.04) 1.68E-01 
FEXOFENADINE HCL 1.12 (0.95 - 1.32) 1.77E-01 
GLIPIZIDE 1.10 (0.96 - 1.26) 1.83E-01 
CARVEDILOL PHOSPHATE 1.22 (0.91 - 1.63) 1.84E-01 
AZITHROMYCIN 1.42 (0.85 - 2.38) 1.84E-01 
LOSARTAN POTASSIUM/HYDROCHLOROTHIAZIDE 1.10 (0.96 - 1.27) 1.85E-01 
OXYBUTYNIN CHLORIDE 0.87 (0.70 - 1.08) 1.98E-01 
LIDOCAINE/PRILOCAINE 1.68 (0.76 - 3.72) 1.99E-01 
LIDOCAINE 1.22 (0.90 - 1.67) 2.00E-01 
LANSOPRAZOLE 0.89 (0.74 - 1.07) 2.02E-01 
CARISOPRODOL 0.76 (0.50 - 1.16) 2.06E-01 
SUCRALFATE 0.79 (0.56 - 1.14) 2.07E-01 
TOLTERODINE TARTRATE 0.88 (0.72 - 1.07) 2.07E-01 
CLINDAMYCIN PHOSPHATE 1.46 (0.81 - 2.65) 2.09E-01 
MOMETASONE FUROATE 0.90 (0.75 - 1.06) 2.10E-01 
ISOSORBIDE MONONITRATE 0.90 (0.75 - 1.07) 2.14E-01 
EXENATIDE 0.83 (0.61 - 1.12) 2.15E-01 
MESALAMINE 1.23 (0.89 - 1.71) 2.15E-01 
NORTRIPTYLINE HCL 0.77 (0.51 - 1.16) 2.17E-01 
DICLOFENAC SODIUM 1.12 (0.93 - 1.36) 2.22E-01 
NYSTATIN/TRIAMCINOLONE ACETONIDE 0.64 (0.32 - 1.31) 2.23E-01 
BACLOFEN 0.73 (0.43 - 1.23) 2.32E-01 
PANTOPRAZOLE SODIUM 1.09 (0.94 - 1.27) 2.33E-01 
TRAZODONE HCL 0.89 (0.73 - 1.08) 2.49E-01 
DOXYCYCLINE MONOHYDRATE 0.68 (0.35 - 1.32) 2.56E-01 
DICYCLOMINE HCL 1.19 (0.88 - 1.62) 2.65E-01 
FLUTICASONE PROPIONATE/SALMETEROL XINAFOATE 0.93 (0.81 - 1.06) 2.67E-01 
ALBUTEROL 0.76 (0.46 - 1.24) 2.70E-01 
SODIUM FLUORIDE 1.24 (0.85 - 1.81) 2.73E-01 
HYDROCORTISONE ACETATE 1.41 (0.76 - 2.61) 2.73E-01 
DABIGATRAN ETEXILATE MESYLATE 0.86 (0.65 - 1.13) 2.75E-01 
COLESEVELAM HCL 1.16 (0.89 - 1.52) 2.82E-01 
HYDROCORTISONE VALERATE 1.74 (0.63 - 4.79) 2.86E-01 
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CLOBETASOL PROPIONATE 0.86 (0.66 - 1.13) 2.89E-01 
PHENAZOPYRIDINE HCL 0.46 (0.11 - 1.97) 2.98E-01 
NAPROXEN 1.11 (0.91 - 1.35) 3.01E-01 
LEVOCETIRIZINE DIHYDROCHLORIDE 1.25 (0.82 - 1.92) 3.02E-01 
TEMAZEPAM 0.87 (0.68 - 1.13) 3.04E-01 
GUAIFENESIN/CODEINE PHOSPHATE 1.56 (0.67 - 3.66) 3.07E-01 
CARVEDILOL 0.94 (0.82 - 1.06) 3.07E-01 
TELMISARTAN 1.15 (0.88 - 1.52) 3.10E-01 
PEG 3350/SODIUM SULFATE/SOD CHLORIDE/KCL/ASCORBATE SOD/VIT 
C 4.26 (0.26 - 69.89) 3.10E-01 
BLOOD-GLUCOSE METER 0.61 (0.24 - 1.58) 3.11E-01 
EZETIMIBE 0.93 (0.82 - 1.07) 3.14E-01 
POLYETHYLENE GLYCOL 3350 0.83 (0.58 - 1.20) 3.26E-01 
MELOXICAM 0.94 (0.82 - 1.07) 3.31E-01 
FLUOROURACIL 1.37 (0.72 - 2.60) 3.31E-01 
ECONAZOLE NITRATE 1.37 (0.72 - 2.60) 3.31E-01 
CIPROFLOXACIN HCL 0.82 (0.54 - 1.23) 3.32E-01 
MECLIZINE HCL 1.19 (0.84 - 1.68) 3.34E-01 
MIRTAZAPINE 0.87 (0.65 - 1.16) 3.36E-01 
NYSTATIN 1.21 (0.81 - 1.79) 3.47E-01 
BENZONATATE 1.31 (0.74 - 2.33) 3.48E-01 
MONTELUKAST SODIUM 0.93 (0.81 - 1.08) 3.48E-01 
NAPROXEN SODIUM 0.71 (0.35 - 1.45) 3.51E-01 
LISINOPRIL 0.97 (0.90 - 1.04) 3.51E-01 
SYRINGE WITH NEEDLEDISPOSABLEINSULIN 1 ML 0.88 (0.67 - 1.15) 3.57E-01 
DEXLANSOPRAZOLE 1.20 (0.82 - 1.75) 3.58E-01 
SCOPOLAMINE 1.84 (0.50 - 6.80) 3.58E-01 
FLUCONAZOLE 0.79 (0.47 - 1.32) 3.64E-01 
PENICILLIN V POTASSIUM 0.38 (0.05 - 3.20) 3.74E-01 
SILVER SULFADIAZINE 0.52 (0.12 - 2.23) 3.78E-01 
KETOCONAZOLE 1.14 (0.85 - 1.51) 3.79E-01 
FEXOFENADINE HCL/PSEUDOEPHEDRINE HCL 1.20 (0.80 - 1.81) 3.81E-01 
HYDROCODONE BITARTRATE/HOMATROPINE METHYLBROMIDE 0.52 (0.12 - 2.24) 3.82E-01 
EPINEPHRINE 1.45 (0.63 - 3.31) 3.84E-01 
BISOPROLOL FUMARATE/HYDROCHLOROTHIAZIDE 0.88 (0.66 - 1.17) 3.86E-01 
QUETIAPINE FUMARATE 0.85 (0.59 - 1.23) 3.92E-01 
FLUOCINONIDE 0.84 (0.56 - 1.26) 3.93E-01 
DILTIAZEM HCL 1.06 (0.93 - 1.20) 3.98E-01 
KETOROLAC TROMETHAMINE 2.02 (0.39 - 10.48) 4.02E-01 
FAMOTIDINE 0.89 (0.68 - 1.17) 4.06E-01 
TERBINAFINE HCL 1.20 (0.78 - 1.85) 4.08E-01 
SITAGLIPTIN PHOSPHATE/METFORMIN HCL 1.11 (0.86 - 1.44) 4.14E-01 
INSULIN DETEMIR 1.12 (0.85 - 1.47) 4.20E-01 
INDOMETHACIN 1.18 (0.79 - 1.76) 4.20E-01 
ESTROGENS CONJUGATED 0.94 (0.79 - 1.10) 4.29E-01 
MINOCYCLINE HCL 0.82 (0.50 - 1.34) 4.30E-01 
LISINOPRIL/HYDROCHLOROTHIAZIDE 0.95 (0.84 - 1.08) 4.40E-01 
TRAMADOL HCL/ACETAMINOPHEN 1.15 (0.80 - 1.64) 4.48E-01 
DESLORATADINE 1.14 (0.81 - 1.61) 4.52E-01 
DICLOFENAC EPOLAMINE 1.33 (0.64 - 2.77) 4.52E-01 
FOLIC ACID 0.91 (0.72 - 1.16) 4.59E-01 
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IMIQUIMOD 0.68 (0.24 - 1.93) 4.63E-01 
BUMETANIDE 1.12 (0.83 - 1.52) 4.64E-01 
BENAZEPRIL HCL 1.09 (0.87 - 1.36) 4.71E-01 
CEPHALEXIN 0.82 (0.49 - 1.39) 4.71E-01 
CALCITONINSALMONSYNTHETIC 1.13 (0.80 - 1.59) 4.79E-01 
NABUMETONE 0.91 (0.69 - 1.19) 4.84E-01 
UREA 1.28 (0.64 - 2.56) 4.85E-01 
DICLOFENAC SODIUM/MISOPROSTOL 0.87 (0.58 - 1.30) 4.93E-01 
NITROGLYCERIN 0.93 (0.75 - 1.15) 4.98E-01 
SIMVASTATIN 1.02 (0.96 - 1.09) 5.02E-01 
ESTRADIOL 0.95 (0.82 - 1.10) 5.06E-01 
INSULIN LISPRO 0.92 (0.71 - 1.18) 5.16E-01 
CLOTRIMAZOLE 1.35 (0.55 - 3.30) 5.17E-01 
GLYBURIDE/METFORMIN HCL 1.09 (0.84 - 1.40) 5.20E-01 
CLONAZEPAM 0.94 (0.78 - 1.14) 5.24E-01 
COLCHICINE 1.09 (0.84 - 1.41) 5.26E-01 
GLYBURIDE 1.06 (0.88 - 1.29) 5.27E-01 
METHOCARBAMOL 1.14 (0.76 - 1.71) 5.31E-01 
ROSUVASTATIN CALCIUM 0.97 (0.87 - 1.08) 5.33E-01 
PROCHLORPERAZINE MALEATE 0.74 (0.28 - 1.94) 5.40E-01 
HYDROXYZINE HCL 1.11 (0.80 - 1.53) 5.41E-01 
BUDESONIDE 1.09 (0.83 - 1.42) 5.42E-01 
AMMONIUM LACTATE 1.20 (0.67 - 2.14) 5.45E-01 
CARBIDOPA/LEVODOPA 0.91 (0.67 - 1.23) 5.51E-01 
IRBESARTAN/HYDROCHLOROTHIAZIDE 0.92 (0.70 - 1.21) 5.59E-01 
INSULIN ASPART 1.07 (0.85 - 1.34) 5.70E-01 
OMEGA-3 ACID ETHYL ESTERS 1.06 (0.87 - 1.29) 5.79E-01 
CLINDAMYCIN HCL 0.71 (0.21 - 2.38) 5.80E-01 
METRONIDAZOLE 0.91 (0.66 - 1.26) 5.83E-01 
FLUOCINOLONE ACETONIDE 0.75 (0.26 - 2.16) 5.99E-01 
AMOXICILLIN/POTASSIUM CLAVULANATE 1.16 (0.66 - 2.04) 5.99E-01 
CYCLOBENZAPRINE HCL 1.05 (0.87 - 1.27) 6.00E-01 
POTASSIUM CHLORIDE 0.98 (0.88 - 1.08) 6.27E-01 
ERYTHROMYCIN BASE 0.61 (0.08 - 4.89) 6.39E-01 
VARDENAFIL HCL 1.08 (0.78 - 1.50) 6.52E-01 
DUTASTERIDE 1.05 (0.86 - 1.27) 6.53E-01 
BUTALBITAL/ACETAMINOPHEN/CAFFEINE 0.89 (0.53 - 1.50) 6.58E-01 
DESOXIMETASONE 1.13 (0.66 - 1.93) 6.63E-01 
TETRACYCLINE HCL 1.13 (0.65 - 1.95) 6.65E-01 
METHYLPREDNISOLONE 0.87 (0.44 - 1.71) 6.77E-01 
RALOXIFENE HCL 1.04 (0.85 - 1.28) 6.98E-01 
MOXIFLOXACIN HCL 0.77 (0.21 - 2.84) 6.99E-01 
DOXYCYCLINE HYCLATE 1.05 (0.81 - 1.38) 7.01E-01 
DARIFENACIN HYDROBROMIDE 0.94 (0.67 - 1.32) 7.07E-01 
CICLOPIROX OLAMINE 1.16 (0.53 - 2.54) 7.09E-01 
ALENDRONATE SODIUM 0.98 (0.87 - 1.10) 7.15E-01 
NITROFURANTOIN MACROCRYSTAL 1.08 (0.73 - 1.59) 7.15E-01 
GABAPENTIN 0.98 (0.86 - 1.11) 7.27E-01 
ONDANSETRON HCL 1.18 (0.45 - 3.12) 7.36E-01 
ESZOPICLONE 0.95 (0.70 - 1.30) 7.53E-01 
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CALCITRIOL 1.06 (0.75 - 1.48) 7.53E-01 
BETAMETHASONE DIPROPIONATE/PROPYLENE GLYCOL 1.10 (0.61 - 1.99) 7.57E-01 
OXYCODONE HCL 0.95 (0.69 - 1.33) 7.77E-01 
SOLIFENACIN SUCCINATE 0.97 (0.77 - 1.21) 7.78E-01 
LIDOCAINE HCL 1.17 (0.39 - 3.50) 7.79E-01 
MEGESTROL ACETATE 0.93 (0.55 - 1.59) 7.99E-01 
TERCONAZOLE 0.76 (0.09 - 6.25) 8.01E-01 
MUPIROCIN 1.09 (0.56 - 2.11) 8.08E-01 
OMEPRAZOLE 1.01 (0.92 - 1.11) 8.10E-01 
FLUTICASONE PROPIONATE 0.99 (0.88 - 1.10) 8.21E-01 
LACTULOSE 0.94 (0.56 - 1.59) 8.23E-01 
ROSIGLITAZONE MALEATE 0.97 (0.73 - 1.29) 8.26E-01 
LEVOFLOXACIN 0.94 (0.55 - 1.61) 8.28E-01 
BETAMETHASONE VALERATE 1.07 (0.57 - 2.00) 8.33E-01 
HYDROCODONE/IBUPROFEN 0.91 (0.33 - 2.48) 8.52E-01 
ONDANSETRON 1.22 (0.14 - 10.59) 8.60E-01 
RABEPRAZOLE SODIUM 1.02 (0.78 - 1.34) 8.71E-01 
DIAZEPAM 1.02 (0.80 - 1.30) 8.82E-01 
PROMETHAZINE HCL 0.97 (0.61 - 1.54) 8.89E-01 
CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE 1.02 (0.73 - 1.45) 8.90E-01 
LEVALBUTEROL TARTRATE 1.03 (0.64 - 1.66) 8.92E-01 
HYDROCORTISONE 1.03 (0.69 - 1.54) 8.98E-01 
BETAMETHASONE DIPROPIONATE 0.96 (0.54 - 1.71) 8.98E-01 
CYANOCOBALAMIN (VITAMIN B-12) 0.98 (0.68 - 1.40) 9.01E-01 
CILOSTAZOL 0.98 (0.70 - 1.38) 9.04E-01 
TRIAMCINOLONE ACETONIDE 0.99 (0.82 - 1.20) 9.07E-01 
NITROFURANTOIN MONOHYDRATE/MACROCRYSTALS 1.03 (0.66 - 1.60) 9.09E-01 
SYRINGE WITH NEEDLEINSULIN DISPOSABLE0.5 ML 0.99 (0.76 - 1.28) 9.11E-01 
TACROLIMUS 0.97 (0.52 - 1.81) 9.17E-01 
TRAMADOL HCL 0.99 (0.85 - 1.15) 9.19E-01 
TORSEMIDE 1.02 (0.74 - 1.38) 9.23E-01 
HYDROXYCHLOROQUINE SULFATE 0.99 (0.74 - 1.32) 9.36E-01 
IPRATROPIUM BROMIDE 1.01 (0.75 - 1.37) 9.36E-01 
PRAVASTATIN SODIUM 1.00 (0.90 - 1.11) 9.41E-01 
MUPIROCIN CALCIUM 0.92 (0.11 - 7.61) 9.42E-01 
NEOMYCIN SULFATE/POLYMYXIN B SULFATE/HYDROCORTISONE 0.96 (0.28 - 3.27) 9.47E-01 
DOXAZOSIN MESYLATE 1.00 (0.82 - 1.23) 9.62E-01 
ALFUZOSIN HCL 1.01 (0.74 - 1.38) 9.67E-01 
SPIRONOLACTONE 1.00 (0.83 - 1.20) 9.72E-01 
CEFADROXIL 1.02 (0.12 - 8.76) 9.84E-01 
HYDROXYZINE PAMOATE 1.01 (0.52 - 1.96) 9.85E-01 
CHOLESTYRAMINE (WITH SUGAR) 1.00 (0.56 - 1.78) 9.88E-01 
IBANDRONATE SODIUM 1.00 (0.84 - 1.20) 9.97E-01 
METAXALONE 1.00 (0.68 - 1.47) 9.98E-01 





Table S7:  Results for multi-drug model association with POAG including all listed drug classes 
as well as hypertension as a comorbidity and adjusted for age, sex, geographic region of 
residence, employment status, insurance plan type, and the total number of drugs prescribed 
for each individual.  P-values significant at Bonferroni-corrected threshold of 2.3 x 10-5 are in 
bold. 
  
OR (95% CI) P-value 
Calcium channel blockers 1.23 (1.14 - 1.33) 2.65E-08 
Beta-blockers 0.73 (0.67 - 0.79) 6.77E-19 
Fibric acid derivatives 0.75 (0.65 - 0.86) 3.17E-05 
Angiotensin II antagonists 1.15 (1.06 - 1.24) 1.10E-03 
Hypertension as a comorbidity 1.21 (1.12 - 1.31) 3.75E-07 





Table S8:  Results from sensitivity analyses with general ophthalmic controls (43,883 controls 
were matched to 6,269 cases) for drug classes and individual drugs significant in primary 
analyses.  P-values significant at the Bonferroni-corrected threshold of 2.3 x 10-5 are in bold. 
  Odds ratio (95% CI) P-value 
USC drug class    
SSRI - Selective Serotonin Reuptake Inhibitors 0.64 (0.58 - 0.69) 6.15E-24 
Beta-blockers 0.77 (0.72 - 0.82) 9.30E-15 
Calcium channel blockers 1.19 (1.12 - 1.28) 2.08E-07 
Sexual function disorders medication 1.22 (1.07 - 1.38) 0.002 
SNRI - Serotonin/Norepinephrine Reuptake Inhibitors 0.64 (0.55 - 0.74) 8.61E-10 
Fibric acid derivatives 0.69 (0.60 - 0.78) 3.38E-09 
Angiotensin II antagonists 1.01 (0.93 - 1.09) 0.84 
     
Generic drug name    
Amlodipine  1.18 (1.10 - 1.27) 1.29E-05 
Citalopram  0.66 (0.57 - 0.77) 7.28E-08 
Esomeprazole  0.72 (0.65 - 0.79) 2.40E-12 
Tamsulosin  0.93 (0.83 - 1.04) 0.23 
      
 
 
